- Report
- March 2024
- 194 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- November 2023
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3123EUR$3,250USD£2,670GBP
- Report
- September 2019
- 29 Pages
Global
€9608EUR$10,000USD£8,215GBP
- Report
- September 2019
- 28 Pages
Global
€9608EUR$10,000USD£8,215GBP
- Report
- March 2019
- 30 Pages
Global
€9608EUR$10,000USD£8,215GBP
Lenvatinib is a drug used to treat certain types of thyroid cancer. It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Lenvatinib is used in combination with other drugs to treat advanced thyroid cancer that has spread to other parts of the body. It is also used to treat thyroid cancer that has not responded to other treatments. Lenvatinib is typically taken orally in the form of a tablet.
The Lenvatinib market is a rapidly growing segment of the thyroid cancer drugs market. It is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. Lenvatinib is a promising treatment option for patients with advanced thyroid cancer, and its use is expected to increase in the coming years.
Some of the companies in the Lenvatinib market include Eisai Co., Ltd., Merck & Co., Inc., and Pfizer Inc. Show Less Read more
